Global Pharma, Biotech and Diagnostics Merger and Acquisition Terms and Agreements Report 2010-2017

Dublin, Oct. 26, 2017 -- The "Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017" report has been added to Research and Markets' offering.

The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, diagnostic and other lifescience sectors. Fully revised and updated, the report provides details of M&A agreements from 2010 to 2017.

The report provides a detailed understanding and analysis of how and why companies enter M&A deals. The majority of deals are acquisitions whereby the acquirer acquires the target company in a cash and/or equity transaction.

Merger and acquisition is a constant activity within the biopharma sector. In the past, biopharma companies have sought to merge or acquire competitor companies in order to achieve critical mass both in R&D and sales and marketing, thus ensuring continued growth and dominance in a highly competitive and global marketplace.

In 1987, the largest ten companies were responsible for approximately twelve percent of global pharmaceutical sales. By 2002, this figure had become nearly fifty percent. This concentration was principally due to big pharma mega mergers.

The rewards offered for the successful marketing and sale of a block buster drug are enormous, therefore it is not surprising to see big pharma seeking ways of maximizing returns. Licensing has often been a means of achieving such global presence, but increasingly big pharma has sought to acquire its way into the major pharmaceutical markets. Until recently the mega merger was a popular means of growing presence globally; however the last few years have seen a concentration on smaller acquisitions to bolster R&D pipelines.

This report focuses on M&A between big pharma-big pharma, big pharma - smaller company, big biotech-big biotech, big biotech - smaller company, and smaller company-smaller company, providing a detailed insight into all such deals.

This report contains links to M&A deal records since 2010 including where availale online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 provides the reader with the following key benefits:

• In-depth understanding of M&A deal trends since 2010
• Analysis of the structure of M&A agreements with numerous real life case studies
• Comprehensive access to over 2,200 actual M&A deals entered into by the world's biopharma companies
• Detailed access to actual M&A deals entered into by the leading fifty bigpharma companies
• Insight into the terms included in a M&A agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in M&A dealmaking

2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2010
2.3.1. M&A dealmaking by year, 2010 to 2017
2.3.2. M&A dealmaking by industry sector, 2010 to 2017
2.3.3. M&A dealmaking by therapy area, 2010 to 2017
2.3.4. M&A dealmaking by most active company, 2010 to 2017
2.4. Key M&A trends
2.5. Option to acquire the new acquisition?
2.5.1. Case study 1: Cephalon - Ception
2.5.2. Case study 2: HertArt Aps - Vitrolife
2.6. When M&A can be useful
2.7. Attributes of M&A deals
2.7.1. M&A as an alternative to IPO
2.8. Partnering deals with M&A component
2.8.1. Partnering as a precursor to M&A
2.8.1.a. Case study 3: Celgene - VentiRx Pharmaceuticals
2.8.2. Equity as part of partnering deal
2.8.2.a. Case study 4: BioMarin - Catalyst Pharma Partners
2.8.2.b. Case study 5: Pfizer - Clovis Oncology
2.8.2.c. Case study 6: Tesaro - OPKO Health
2.8.3. Conversion of partnership to acquisition
2.8.4. But M&A is not always the route followed
2.9. Big pharma mega mergers - are we at the end of the road?
2.9.1. Growth of Johnson & Johnson through M&A
2.9.2. Growth of Novartis through M&A
2.10. Accessing innovation through M&A
2.10.1. Big pharma acquisitions of small companies
2.10.1.a. Case study 7: Abbott - Facet Biotechnology
2.10.1.b. Case study 8: Gilead Sceinces - Pharmasset
2.10.2. Medium and small biopharma - use of M&A
2.10.2.a. Case study 9: Allergan - MAP Pharmaceuticals
2.10.2.b. Case study 10: Reckitt Benckiser - Schiff Nutrition International
2.10.3. Using M&A to build a company
2.10.3.a. Case study 11: Shire - built from M&A
2.10.3.b. Case study 12: Zeneus - acquiring a ready-made European capability
2.10.3.c. Case study 13: Novartis - from pure pharma to half generic
2.10.4. Emergence of biotech-biotech mergers
2.10.4.a. Case study 14: Merger between Biogen and Idec
2.10.4.b. Case study 15: Amgen acquisition activity
2.11. The emerging role of private equity in M&A
2.12. Implementing M&A transactions
2.13. Joint ventures as alternative to M&A
2.14. The future of M&A in biopharma

Chapter 3 - Overview of M&A deal structure

3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.3.1. Example acquisition agreements
3.3.1.a. Case study 16: Allergan - SkinMedica
3.4. Acquisition as part of a wider alliance agreement
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 17: MGI Pharma - AkaRx
3.5. Merger agreements
3.5.1. Example merger agreements
3.5.1.a. Case study 18: Synergy Pharmaceuticals - Callisto Pharmaceuticals

Chapter 4 - Leading M&A deals

4.1. Introduction
4.2. Top M&A deals by value

Chapter 5 - Top 50 most active M&A dealmakers

5.1. Introduction
5.2. Top 50 most active M&A dealmakers

Chapter 6 - M&A contract directory 2010- 2017

6.1. Introduction
6.2. M&A deals with contracts 2010 to 2017

For more information about this report visit https://www.researchandmarkets.com/research/2mg5tn/global_merger_and

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Biotechnology, Pharmaceuticals, Diagnostics